Lexicon Pharmaceuticals has resubmitted its New Drug Application (NDA) for sotagliflozin, aimed at improving glycemic control in people with type 1 diabetes and chronic kidney disease (CKD).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,